BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31865248)

  • 1. Myeloid neoplasm with eosinophilia and BCR-JAK2/t(9;22)(p24;q11.2) morphologically mimicking chronic myeloid leukemia.
    Thakral B; Muzzafar T; Wang SA; Medeiros LJ
    Ann Diagn Pathol; 2020 Feb; 44():151405. PubMed ID: 31865248
    [No Abstract]   [Full Text] [Related]  

  • 2. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia.
    Cirmena G; Aliano S; Fugazza G; Bruzzone R; Garuti A; Bocciardi R; Bacigalupo A; Ravazzolo R; Ballestrero A; Sessarego M
    Cancer Genet Cytogenet; 2008 Jun; 183(2):105-8. PubMed ID: 18503828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
    Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
    Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
    He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
    Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia.
    Xu Y; Yin J; Pan J; Wu C; Wang Q; Yao H; Wu D; Chen S; Sun A
    Leuk Lymphoma; 2013 Oct; 54(10):2322-4. PubMed ID: 23432689
    [No Abstract]   [Full Text] [Related]  

  • 6. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.
    Snider JS; Znoyko I; Lindsey KG; Morse J; Baughn LB; Hoppman NL; Pitel BA; Pearce KE; Schandl CA; Wolff DJ
    Cancer Genet; 2020 Aug; 246-247():44-47. PubMed ID: 32827877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.
    Bader G; Dreiling B
    J Investig Med High Impact Case Rep; 2019; 7():2324709619832322. PubMed ID: 30803277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion.
    Lane SW; Fairbairn DJ; McCarthy C; Nandini A; Perry-Keene J; Kennedy GA
    Br J Haematol; 2008 Aug; 142(4):503. PubMed ID: 18537978
    [No Abstract]   [Full Text] [Related]  

  • 9. Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.
    Kantarcioglu B; Kaygusuz-Atagunduz I; Uzay A; Toptas T; Tuglular TF; Bayik M
    Int J Hematol; 2015 Sep; 102(3):383-7. PubMed ID: 25833723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
    Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Myeloid Leukemia as Secondary Malignancy Following the Treatment of Hodgkin Lymphoma: A Case Series.
    Millett R; Aggarwal A; Tabbara I; Nassereddine S
    Anticancer Res; 2019 Aug; 39(8):4333-4335. PubMed ID: 31366526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
    Turakhia SK; Murugesan G; Cotta CV; Theil KS
    J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.
    Lund HL; Hughesman CB; McNeil K; Clemens S; Hocken K; Pettersson R; Karsan A; Foster LJ; Haynes C
    Anal Bioanal Chem; 2016 Feb; 408(4):1079-94. PubMed ID: 26631023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].
    Amemiya A; Ito Y; Ishibashi Y; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Ohyashiki K
    Rinsho Ketsueki; 2017; 58(4):298-302. PubMed ID: 28484156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm.
    De Bruyne S; Steel E; Petrick M; Denys B; Vandepoele K; Van Roy N; Degandt S; Ghys T; Louagie H
    Clin Chem Lab Med; 2021 Sep; 59(10):e392-e394. PubMed ID: 33964201
    [No Abstract]   [Full Text] [Related]  

  • 16. Dehydrocostus Lactone Suppresses Proliferation of Human Chronic Myeloid Leukemia Cells Through Bcr/Abl-JAK/STAT Signaling Pathways.
    Cai H; Qin X; Yang C
    J Cell Biochem; 2017 Oct; 118(10):3381-3390. PubMed ID: 28300289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two alternatively spliced 5'BCR/3'JAK2 fusion transcripts in a myeloproliferative neoplasm with a three-way t(9;18;22)(p23;p11.3;q11.2) translocation.
    Impera L; Lonoce A; Fanfulla DA; Moreilhon C; Legros L; Raynaud S; Storlazzi CT
    Cancer Genet; 2011 Sep; 204(9):512-5. PubMed ID: 22018274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.
    Duployez N; Nibourel O; Ducourneau B; Grardel N; Boyer T; Bories C; Darre S; Coiteux V; Berthon C; Preudhomme C; Roche-Lestienne C
    Eur J Haematol; 2016 Oct; 97(4):399-402. PubMed ID: 26935241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-JAK2 drives a myeloproliferative neoplasm in transplanted mice.
    Cuesta-Domínguez Á; León-Rico D; Álvarez L; Díez B; Bodega-Mayor I; Baños R; Martín-Rey MÁ; Santos-Roncero M; Gaspar ML; Martín-Acosta P; Almarza E; Bueren JA; Río P; Fernández-Ruiz E
    J Pathol; 2015 Jun; 236(2):219-28. PubMed ID: 25664618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
    McCarron SL; Haslam K; Crampe M; Langabeer SE
    Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.